Ensilica PLC ENSI
LSE · Vereinigtes Königreich · Elektronische Technologie
GBp 74,03+2,03 (+2,82 %)
Markt geöffnet· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geöffnet· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Coiled Therapeutics (AIM:COIL) is introducing a new softgel formulation of its lead cancer drug candidate AO-252 to improve absorption and consistency. The first patient is expected to be dosed this month, with data from expansion cohorts due in the second half of the year. IXICO (LSE:IXI) has upgraded its revenue forecast to at least £8 million for the current financial year, up from earlier guidance of £7.5 million. That represents growth of around 22% on last year, driven by new contract wins and a broader client base. EnSilica (AIM:ENSI) has raised around £14 million through an oversubscri
The United Kingdom's stock market has recently faced challenges, with the FTSE 100 index slipping due to weak trade data from China, highlighting the interconnectedness of global economies. In such a fluctuating market environment, identifying growth companies with significant insider ownership can be appealing as it often indicates confidence in the company's potential and aligns management interests with those of shareholders.
As the FTSE 100 and FTSE 250 indices in the United Kingdom experience downward pressure due to weak trade data from China, investors are closely watching how global economic challenges impact domestic markets. In such uncertain times, growth companies with high insider ownership can be appealing as they often indicate strong internal confidence and alignment of interests between management and shareholders.
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.